title: Medical treatment of an adult with uncorrected isolated interrupted aorta resulted in no complications after 4 years of follow-up.
abstract: METHODS
  Female, 56.
  
  
  METHODS
  Isolated adult interrupted aortic arch.
  
  
  METHODS
  Headache • hypertension • left ventricular hypertrophy.
  
  
  METHODS
  -.
  
  
  METHODS
  -.
  
  
  METHODS
  Surgery.
  
  
  OBJECTIVE
  Congenital defects/diseases.
  
  
  BACKGROUND
  Interrupted aorta is a rare congenital malformation defined as the lack of continuity between the ascending and descending parts of the aorta.
  
  
  METHODS
  This malformation was first described by Steidele in 1778. To date a few isolated adult interrupted aortic arch patients have been reported and most of them were treated surgically. However, there is not data about outcome of patients who decline surgery or who are not good candidates for surgery because of excessive risks, and there is not a data about how to follow these patients.
  
  
  CONCLUSIONS
  Herein we present a case of adult type A isolated interrupted aorta followed-up for 4 years by medical therapy without complications.
authors.affiliation: Department of Cardiology, Sifa University, Izmir, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Öztürk
authors.affiliation: Department of Cardiology, Sifa University, Izmir, Turkey.
authors.forename: Emin Evren
authors.initials: EE
authors.lastname: Özcan
authors.affiliation: Department of Cardiology, Sifa University, Izmir, Turkey.
authors.forename: Erdem
authors.initials: E
authors.lastname: Özel
authors.affiliation: Department of Cardiology, Sifa University, Izmir, Turkey.
authors.forename: Samet
authors.initials: S
authors.lastname: Uyar
authors.affiliation: Department of Cardiology, Sifa University, Izmir, Turkey.
authors.forename: Ömer
authors.initials: Ö
authors.lastname: Senaslan
mesh_terms: D000792:Angiography; D000804:Angiotensin II; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D001013:Aorta, Thoracic / Q000002:abnormalities* / Q000000981:diagnostic imaging; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004095:Dihydropyridines / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D000077405:Irbesartan; D008875:Middle Aged; D061330:Multidetector Computed Tomography; D013777:Tetrazoles / Q000627:therapeutic use*; D013997:Time Factors; D054079:Vascular Malformations / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D004232:Diuretics; D013777:Tetrazoles; D006852:Hydrochlorothiazide; D000804:Angiotensin II; D000077405:Irbesartan; C060343:lercanidipine
references.citation: Ann Thorac Surg. 2000 Apr;69(4 Suppl):S298-307
references.pmid: 10798436
references.citation: Tex Heart Inst J. 2002;29(2):118-21
references.pmid: 12075868
references.citation: Tex Heart Inst J. 2011;38(5):559-61
references.pmid: 22163135
references.citation: AJR Am J Roentgenol. 2008 Jun;190(6):1467-74
references.pmid: 18492893
references.citation: Eur J Cardiothorac Surg. 2009 Apr;35(4):569-76
references.pmid: 19233679
references.citation: Schweiz Med Wochenschr. 1995 Jan 10;125(1-2):26-30
references.pmid: 7839106
references.citation: Tex Heart Inst J. 2012;39(3):398-400
references.pmid: 22719153